Abstract
This study focused on PTEN and Livin expression and associations with malignancy in human renal clear cell carcinomas (RCCC). PTEN and Livin expression was assessed in 100 RCCC tissue samples, 50 paracarcinoma cases, and 20 normal renal tissue samples using the immunohistochemical Streptavidin proxidase (SP) method. The relationships between binding and corresponding biological characteristics, such as histological grade, lymph node metastases, and clinical stages were analyzed. Positive PTEN expression in RCCC was significantly lower than in renal tissue adjacent to carcinoma tissue and normal renal tissue (P<0.01). Livin expression in the renal tissue adjacent to the carcinoma and normal renal tissues exhibited only low levels, whereas overall Livin expression in RCCC was statistically significant (P<0.01). In RCCC, PTEN expression rate gradually decreased with an increase in clinical stage, whereas that of Livin increased to statistically significant levels (P<0.01), PTEN and Livin levels being negatively correlated (r=-0.395, P<0.01). PTEN and Livin are important in RCCC development. The two factors combined are expected to provide indices for estimating RCCC malignancy and progression levels, as well as references for RCCC diagnosis and treatment.
Highlights
Renal cell carcinoma is the second most common urinary system cancer after bladder cancer
This study focused on Phosphatase and tensin homologue (PTEN) and Livin expression and associations with malignancy in human renal clear cell carcinomas (RCCC)
In RCCC, PTEN expression rate gradually decreased with an increase in clinical stage, whereas that of Livin increased to statistically significant levels (P
Summary
Renal cell carcinoma is the second most common urinary system cancer after bladder cancer. Phosphatase and tensin homologue (PTEN), known as TGF-βregulated and epithelial cell-enriched phosphatase or muted in multiple advanced cancers gene (Trotman et al, 2007), is a human tumor suppressor gene with the highestlost rate after P53 and the highest mutation rate (Huang and Kontos, 2002). PTEN contains a PDZ (post synaptic density protein-q5, Drosophila disc large tumor suppressor, and zonula occludens-1) binding sequence, bird creatinine kinase-2 or -3 (melanoma antigen gene), and PDZ domain-binding and epithelial tight junctions, which regulate the AKT/ PKB pathway. PTEN is a proven tumor suppressor gene phosphatase inhibitor closely related to the mutation and development of several human malignancies, including breast cancer, glial brain cell tumors, bladder cancer, and prostate cancer (Hager, 2007)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
